CYC065: Clinical Trials

7 trials of CYC065, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 recruiting, 1 suspended, 1 unknown. 6 Phase 1, 3 Phase 2, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 16Completed 3, Recruiting 1, Suspended 1, Unknown 1
Phase 23Recruiting 1, Suspended 1, Unknown 1
Early Phase 11Completed 1

Follow CYC065: new trials by email Literature Review of CYC065 trials Research Report on CYC065

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects
Fadraciclib - Healthy
Early Phase 1CompletedCyclacel Pharmaceuticals, Inc.82023-03-032024-09-19
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
fadraciclib - Leukemia, Myelodysplastic Syndrome(MDS)
Phase 1 / Phase 2SuspendedCyclacel Pharmaceuticals, Inc.2102021-10-222024-02-08
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Fadraciclib - Solid Tumor, Adult, Lymphoma
Phase 1 / Phase 2UnknownCyclacel Pharmaceuticals, Inc.3302021-07-122024-01-25
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
CYC065, Venetoclax - AML, MDS
Phase 1CompletedCyclacel Pharmaceuticals, Inc.142019-08-022024-09-19
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
CYC065, Venetoclax - Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 1CompletedCyclacel Pharmaceuticals, Inc.52019-01-252024-01-25
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Ribociclib, Topotecan, Temozolomide - Pediatric Cancer
Phase 1 / Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris4722016-08-032026-07-10
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
CYC065 - Cancer
Phase 1CompletedCyclacel Pharmaceuticals, Inc.602015-09-282024-05-31

Conditions studied

Myelodysplastic Syndromes (2)  ·  Neoplasms (2)  ·  Recurrence (2)  ·  Leukemia (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lymphoma (1)

Sponsors

Cyclacel Pharmaceuticals, Inc. (6)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)

Countries

United States (6)  ·  Spain (2)  ·  Denmark (1)  ·  France (1)  ·  Italy (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  United Kingdom (1)

Top investigators

Birgit Geoerger, MD (1)  ·  Gautam Borthakur, MD (1)  ·  Geoffrey Shapiro, MD (1)  ·  Mark H Kirschbaum, MD (1)  ·  Mark Kirschbaum, MD (1)

Results publications

PMID 31538815, PMID 32645016, PMID 33892407, PMID 34347542, PMID 34543871, PMID 35292802, PMID 41838385, PMID 42686334

NIH funding

2016 (1)